WuXi PharmaTech Launches Mobile OncoWuXi, the World's First App for Accessing Oncology Models
SHANGHAI, Oct. 13, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that it has launched a mobile version of OncoWuXi, the first App in the world to allow researchers to access oncology models and data on the go. The OncoWuXi App helps WuXi's clients anywhere and at any time to identify relevant tumor models for use in anti-tumor efficacy testing to facilitate oncology drug discovery and translational oncology, as well as to keep up-to-date on WuXi's capabilities and services in this area.
The OncoWuXi App provides users with a portable oncology database for selection and inquiry of the more than 1,000 cancer patient-derived xenograft (PDX), human cancer cell-derived xenograft (CDX), and syngeneic mouse tumor models available at WuXi. Its backend database covers every aspect of those models, including growth dynamics, histopathology, clinical information, genomic profiles, and Standard of Care (SoC) validation data. Users may also submit service requests regarding particular models from the App directly to WuXi Oncology.
The App can be used on either Apple or Android devices and is available for download at both the Apple App store and Google Play. Its corresponding web-based browser, http://onco.wuxiapptec.com/, was launched in China in June and is also accessible globally.
"WuXi has long been committed to bringing our customers the most advanced products and services for discovering and developing innovative drugs," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "Beginning with WuXi V-Lab, the first mobile app available to the global research community in need of small-molecule compound synthesis, which we launched earlier this year, and now with OncoWuXi, we are striving to enable our customers to access our platform capabilities and technologies more quickly and easily."
For an Android device, OncoWuXi App can be downloaded at http://onco.wuxiapptec.com/oncowuxi.apk.
About WuXi PharmaTech
WuXi PharmaTech is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of services throughout the drug and medical device R&D process. WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com.
For more information, please contact:
Ronald Aldridge (for investors)
LaVoieHealthScience
+1-617-374-8800 x109
+1 617-792-2459
[email protected]
Aaron Shi (for the media)
Director, Corporate Communications
WuXi PharmaTech
+86-21-5046-4362
[email protected]
SOURCE WuXi PharmaTech (Cayman) Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article